| Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study S de Sanjose, WGV Quint, L Alemany, DT Geraets, JE Klaustermeier, ... The lancet oncology 11 (11), 1048-1056, 2010 | 3075 | 2010 |
| Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases SM Garland, M Hernandez-Avila, CM Wheeler, G Perez, DM Harper, ... New England Journal of Medicine 356 (19), 1928-1943, 2007 | 2527 | 2007 |
| Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a … J Paavonen, P Naud, J Salmerón, CM Wheeler, SN Chow, D Apter, ... The Lancet 374 (9686), 301-314, 2009 | 2104 | 2009 |
| A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women EA Joura, AR Giuliano, OE Iversen, C Bouchard, C Mao, J Mehlsen, ... New England Journal of Medicine 372 (8), 711-723, 2015 | 1731 | 2015 |
| Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis DA Machalek, M Poynten, F Jin, CK Fairley, A Farnsworth, SM Garland, ... The lancet oncology 13 (5), 487-500, 2012 | 1164 | 2012 |
| Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis M Drolet, É Bénard, N Pérez, M Brisson, H Ali, MC Boily, V Baldo, ... The Lancet 394 (10197), 497-509, 2019 | 1029 | 2019 |
| A review of clinical trials of human papillomavirus prophylactic vaccines JT Schiller, X Castellsagué, SM Garland Vaccine 30, F123-F138, 2012 | 954 | 2012 |
| High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence CS Bradshaw, AN Morton, J Hocking, SM Garland, MB Morris, LM Moss, ... The Journal of infectious diseases 193 (11), 1478-1486, 2006 | 922 | 2006 |
| Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double … M Lehtinen, J Paavonen, CM Wheeler, U Jaisamrarn, SM Garland, ... The lancet oncology 13 (1), 89-99, 2012 | 918 | 2012 |
| Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined … EA Joura, S Leodolter, M Hernandez-Avila, CM Wheeler, G Perez, ... The Lancet 369 (9574), 1693-1702, 2007 | 861 | 2007 |
| The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in … DR Brown, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... The Journal of infectious diseases 199 (7), 926-935, 2009 | 712 | 2009 |
| Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine SM Garland, M Steben, HL Sings, M James, S Lu, R Railkar, E Barr, ... The Journal of infectious diseases 199 (6), 805-814, 2009 | 648 | 2009 |
| Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis … CM Wheeler, X Castellsagué, SM Garland, A Szarewski, J Paavonen, ... The lancet oncology 13 (1), 100-110, 2012 | 644 | 2012 |
| Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience SM Garland, SK Kjaer, N Muñoz, SL Block, DR Brown, MJ DiNubile, ... Reviews of Infectious Diseases 63 (4), 519-527, 2016 | 643 | 2016 |
| Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts … Future I/II Study Group The BMJ 341, 2010 | 555 | 2010 |
| Web-based recruiting for health research using a social networking site: an exploratory study Y Fenner, SM Garland, EE Moore, Y Jayasinghe, A Fletcher, SN Tabrizi, ... Journal of medical Internet research 14 (1), e20, 2012 | 530 | 2012 |
| Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial WK Huh, EA Joura, AR Giuliano, OE Iversen, RP de Andrade, KA Ault, ... The Lancet 390 (10108), 2143-2159, 2017 | 522 | 2017 |
| Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women N Muñoz, SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, ... Journal of the National Cancer Institute 102 (5), 325-339, 2010 | 485 | 2010 |
| Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data EA Joura, SM Garland, J Paavonen, DG Ferris, G Perez, KA Ault, WK Huh, ... Bmj 344, 2012 | 437 | 2012 |
| A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions SK Kjaer, K Sigurdsson, OE Iversen, M Hernandez-Avila, CM Wheeler, ... Cancer prevention research 2 (10), 868-878, 2009 | 419 | 2009 |
